Table 3.
Cytotoxicity data of selected metallacycles against a panel of human cancer cells.
| Com-pound | IC50 (hrs of incubation)/Type of cells (IC50 of ref. compound) | IC50 (hrs of incubation)/Type of cells (IC50 of ref. compound) | IC50 (hrs of incubation)/Type of cells (IC50 of ref. compound) | IC50 (hrs of incubation)/Type of cells (IC50 of ref. compound) | References |
|---|---|---|---|---|---|
| 6a | 20.0 ± 0.2 μM(48 h)/A549 (25.0 ± 0.3/CDDP) | 05.0 ± 0.2 μM(48 h)/MCF7 (20.0 ± 0.3/CDDP) | 16.0 ± 0.4 μM(48 h)/KB (8.0 ± 0.4/CDDP) | 16.0 ± 0.5 μM(48 h)/HaCaT (12.0 ± 0.3/CDDP) | Bhowmick et al., 2018 |
| 6b | 19.4 ± 0.5 μM HT-29 (1-10/CDDP) | 9.1 ± 0.1 μM MCF-7 (1-10/CDDP) | 9.6 ± 0.9 μM MDA-MB-231 (1-10/CDDP) | 10.4 ± 0.2 μMRC-124 (1-10/CDDP) | Jana et al., 2018 |
| 7 | >30.0 μM (48 h)/A549 (25.0 ± 0.3/CDDP) | 17.0 ± 0.3 μM(48 h)/MCF7 (20.0 ± 0.3/CDDP) | 20.0 ± 0.1 μM(48 h)/KB (8.0 ± 0.4/CDDP) | 20.0 ± 0.1 μM(48 h)/HaCaT (12.0 ± 0.3/CDDP) | Bhowmick et al., 2018 |
| A6 | 21.54 ± 3.2 μM (48 h)/A549 (22.38 ± 2.9 /CDDP) | 14.28 ± 1.2 μM(48 h)/HepG2 (18.89 ± 2.1 /CDDP) | 19.55 ± 2.5 μM(48 h)/HeLa (10.21 ± 1.9/CDDP) | Jana et al., 2019 | |
| 11 | 10.22 ± 1.6 μM (48 h)/A549 (22.38 ± 2.9 /CDDP) | 11.02 ± 1.3 μM(48 h)/HepG2 (18.89 ± 2.1/CDDP) | 8.73 ± 1.0 μM(48 h)/HeLa (10.21 ± 1.9/CDDP) | Jana et al., 2019 | |
| 13 | 5.2 ± 2.0 μM/T98G (69.6 ± 7.9 /CDDP) | 15.5 ± 2.3 μM/KB (72.6 ± 6.2 /CDDP) | 18.3 ± 3.0 μM/SNU80 (49.3 ± 5.4 /CDDP) | 36.2 ± 5.1 μM/HEK293 (17.3 ± 3.6 /CDDP) | Mishra et al., 2014 |
| 14 | 4.5 ± 2.1 μM/T98G (69.6 ± 7.9 /CDDP) | 13.0 ± 1.2 μM/KB (72.6 ± 6.2 /CDDP) | 12.0 ± 2.8 μM/SNU80 (49.3 ± 5.4 /CDDP) | 35.0 ± 3.8 μM/HEK293 (17.3 ± 3.6 /CDDP) | Mishra et al., 2014 |
Cell types given in bold are normal non-cancerous cells.